Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001381032 | SCV001579284 | pathogenic | Majeed syndrome | 2022-03-07 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 1069224). This variant has not been reported in the literature in individuals affected with LPIN2-related conditions. This variant is present in population databases (rs762442011, gnomAD 0.006%). This sequence change creates a premature translational stop signal (p.Lys781Thrfs*7) in the LPIN2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in LPIN2 are known to be pathogenic (PMID: 15994876, 23087183). |
Prevention |
RCV004731143 | SCV005335783 | likely pathogenic | LPIN2-related disorder | 2024-09-24 | no assertion criteria provided | clinical testing | The LPIN2 c.2342_2346del5 variant is predicted to result in a frameshift and premature protein termination (p.Lys781Thrfs*7). To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0033% of alleles in individuals of South Asian descent in gnomAD. Frameshift variants in LPIN2 are expected to be pathogenic. This variant is interpreted as likely pathogenic. |